会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • E. coli extract for protein synthesis
    • 大肠杆菌提取物用于蛋白质合成
    • US20020034559A1
    • 2002-03-21
    • US09848449
    • 2001-05-03
    • Yuping AmbuelThomas R. Van OosbreeMark R. McCormickRobert C. Mierendorf
    • A61K035/66A61K035/68C12P021/06A01N063/02
    • C07K14/245C12P21/02
    • There is now a market for kits containing the necessary components for performing protein synthesis reactions using template DNA of the experimenter. One category of existing system for performing protein synthesis reactions is based on an S-30 extract from the bacteria E. coli. It is disclosed here that a simple fractionation process can dramatically improve the performance of an S-30 prokaryotic protein synthesis reaction mixture. In one embodiment, the fractionation is a simple freezing and thawing of an S-30 extract combined with a supplemental mix, followed by centrifugation. The resulting fractionated S-30 reaction mixture yields more full-length target protein and less non-full length or non-target protein than possible using prior art S-30 systems.
    • 现在有一个包含使用实验者的模板DNA进行蛋白质合成反应的必要组分的试剂盒的市场。 用于进行蛋白质合成反应的现有系统的一个类别是基于来自细菌大肠杆菌的S-30提取物。 这里公开了简单的分级方法可以显着改善S-30原核生物蛋白质合成反应混合物的性能。 在一个实施方案中,分馏是与补充混合物组合的S-30提取物的简单冷冻和解冻,然后离心。 所得到的分级的S-30反应混合物比现有技术的S-30系统产生更多的全长靶蛋白和较少的非全长或非靶蛋白。
    • 6. 发明申请
    • Kefir extract as anti-cancer agent
    • Kefir提取物作为抗癌剂
    • US20040033282A1
    • 2004-02-19
    • US10311504
    • 2003-07-14
    • Stan KubowLaurie Hing Man ChanChujian ChenMaryam Fotouhinia
    • A61K035/68
    • A61K35/20
    • The present invention relates to an anti-cancer composition having anti-proliferative and/or inhibitory effects specifically targeted at malignant cells, which comprises a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir in association with a pharmaceutically acceptable carrier. The present invention also relates to a method of inhibiting proliferation of malignant cells in patient, which comprises administering an effective amount of a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir. The present invention also relates to a prophylactic composition having neutraceutical properties, which comprises a filtrated bacteria-free and/or yeast-free liquid extract of initial fermentative kefir in association with a pharmaceutically acceptable carrier.
    • 本发明涉及具有特异性靶向恶性细胞的抗增殖和/或抑制作用的抗癌组合物,其包括与药学上可接受的相关联的初始发酵性发酵胃蛋白的过滤的无细菌和/或无酵母液体提取物 载体 本发明还涉及一种抑制患者恶性细胞增殖的方法,其包括施用有效量的初始发酵性胃蛋白酶的无过滤的无细菌和/或无酵母液体提取物。 本发明还涉及具有营养学性质的预防组合物,其包含与药学上可接受的载体相关联的初始发酵性发酵胃蛋白的过滤的无细菌和/或无酵母液体提取物。